NCT05522517View on ClinicalTrials.gov

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

November 2, 2022

Study Completion Date

November 2, 2022

Conditions
Healthy
Interventions
DRUG

Cosentyx

Cosentyx injection will be administered subcutaneously.

DRUG

Candin

Candin will be administered interadermally along with NaCl solution.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Antwerp

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY